First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children

PLoS ONE

Volumn 13, Issue 12, 2018, Pages

  Tiono, Alfred B ^a   Nébié, Issa ^a   Anagnostou, Nicholas ^b   Coulibaly, Aboubacar S ^a   Bowyer, Georgina ^b   Lam, Erika ^b   Bougouma, Edith C ^a   Ouedraogo, Alphonse ^a   Yaro, Jean Baptist B ^a   Barry, Aïssata ^a   Roberts, Rachel ^b   Rampling, Tommy ^b   Bliss, Carly ^b   Hodgson, Susanne ^b   Lawrie, Alison ^b   Ouedraogo, Amidou ^a   Imoukhuede, Egeruan Babatunde ^f   Ewer, Katie J ^b   Viebig, Nicola K ^c   Diarra, Amidou ^a   Leroy, Odile ^c   Bejon, Philip ^d   Hill, Adrian V S ^b   Sirima, Sodiomon B ^a,e   more..

^a Burkina Faso   (Burkina Faso)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^d KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^e Centre de Recherche Action en Sante GRAS   (Burkina Faso)

^f NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHIMPANZEE ADENOVIRUS 63 MULTI EPITOPE STRING THROMBOSPONDIN RELATED ADHESION PROTEIN VECTORED VACCINE; DIPLOID CELL VACCINE; MALARIA VACCINE; MODIFIED VACCINIA VIRUS ANKARA MULTI EPITOPE STRING THROMBOSPONDIN RELATED ADHESION PROTEIN VECTORED VACCINE; RABIES VACCINE; UNCLASSIFIED DRUG;

ARTICLE; BURKINA FASO; CHILD; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ENDEMIC DISEASE; FEMALE; FEVER; FOLLOW UP; HUMAN; IMMUNE RESPONSE; INFANT; INFECTION PREVENTION; IRRITABILITY; LOSS OF APPETITE; MALARIA; MALE; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; T LYMPHOCYTE; TIME TO TREATMENT; VACCINATION; VACCINE IMMUNOGENICITY; CLINICAL TRIAL; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; IMMUNOLOGY; KAPLAN MEIER METHOD; KENYA; METABOLISM; MONONUCLEAR CELL; PATHOGENICITY; PLASMODIUM FALCIPARUM; SIMIAN VIRUS; VACCINIA VIRUS;

ADENOVIRUSES, SIMIAN; DOUBLE-BLIND METHOD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INFANT; KAPLAN-MEIER ESTIMATE; KENYA; LEUKOCYTES, MONONUCLEAR; MALARIA; MALARIA VACCINES; MALE; PLASMODIUM FALCIPARUM; T-LYMPHOCYTES; VACCINIA VIRUS;

EID: 85058455428     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0208328     Document Type: Article

References (26)

1. WHO (2017) World Malaria Report 2017. http://appswhoint/iris/bitstream/10665/259492/1/ 9789241565523-engpdf:196.
2. Snow RW, Sartorius B, Kyalo D, Maina J, Amratia P, Mundia CW, et al. (2017) The prevalence of Plasmodium falciparum in sub-Saharan Africa since 1900. Nature 550: 515–518. https://doi.org/10.1038/ nature24059 PMID: 29019978
3. Das P, Horton R (2010) Malaria elimination: worthy, challenging, and just possible. The Lancet 376: 1515–1517.
4. Moorthy VS, Newman RD, Okwo-Bele JM (2013) Malaria vaccine technology roadmap. Lancet 382: 1700–1701.
5. Greenwood B, Doumbo OK (2016) Implementation of the malaria candidate vaccine RTS,S/AS01. Lancet 387: 318–319. https://doi.org/10.1016/S0140-6736(15)00807-7 PMID: 26549465
6. Vandoolaeghe P, Schuerman L (2016) The RTS,S/AS01 malaria vaccine in children 5 to 17 months of age at first vaccination. Expert Rev Vaccines 15: 1481–1493. https://doi.org/10.1080/14760584.2016. 1236689 PMID: 27841689
7. WHO (2018) Q&A on the malaria vaccine implementation programme (MVIP). WHO.
8. Ewer KJ, O’Hara GA, Duncan CJ, Collins KA, Sheehy SH, Reyes-Sandoval A, et al. (2013) Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. Nat Commun 4: 2836. https://doi.org/10.1038/ncomms3836 PMID: 24284865
9. Mensah VA, Gueye A, Ndiaye M, Edwards NJ, Wright D, Anagnostou NA, et al. (2016) Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal. PLoS One 11: e0167951. https://doi.org/10.1371/journal.pone.0167951 PMID: 27978537
10. Ogwang C, Kimani D, Edwards NJ, Roberts R, Mwacharo J, Bowyer G, et al. (2015) Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against Plasmodium falciparum infection in Kenyan adults. Sci Transl Med 7: 286re285.
11. Ogwang C, Kimani D, Edwards NJ, Roberts R, Mwacharo J, Bowyer G, et al. (2015) Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against Plasmodium falciparum infection in Kenyan adults. Sci Transl Med 7: 286re285.
12. Afolabi MO, Tiono AB, Adetifa UJ, Yaro JB, Drammeh A, Nebie I, et al. (2016) Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and Infants. Mol Ther 24: 1470–1477. https://doi.org/10.1038/mt.2016.83 PMID: 27109630
13. Bliss CM, Drammeh A, Bowyer G, Sanou GS, Jagne YJ, Ouedraogo O, et al. (2017) Viral Vector Malaria Vaccines Induce High-Level T Cell and Antibody Responses in West African Children and Infants. Mol Ther 25: 547–559. https://doi.org/10.1016/j.ymthe.2016.11.003 PMID: 28153101
14. Mensah VA, Roetynck S, Kanteh EK, Bowyer G, Ndaw A, Oko F, et al. (2017) Safety and Immunogenicity of Malaria Vectored Vaccines Given with Routine Expanded Program on Immunization Vaccines in Gambian Infants and Neonates: A Randomized Controlled Trial. Front Immunol 8: 1551. https://doi.org/10.3389/fimmu.2017.01551 PMID: 29213269
15. Kangoye DT, Nebie I, Yaro JB, Debe S, Traore S, Ouedraogo O, et al. (2014) Plasmodium falciparum malaria in children aged 0–2 years: the role of foetal haemoglobin and maternal antibodies to two asexual malaria vaccine candidates (MSP3 and GLURP). PLoS One 9: e107965. https://doi.org/10.1371/journal.pone.0107965 PMID: 25238160
16. Tiono AB, Kangoye DT, Rehman AM, Kargougou DG, Kabore Y, Diarra A, et al. (2014) Malaria incidence in children in South-West Burkina Faso: comparison of active and passive case detection methods. PLoS One 9: e86936. https://doi.org/10.1371/journal.pone.0086936 PMID: 24475198
17. Nebie I, Edwards NJ, Tiono AB, Ewer KJ, Sanou GS, Soulama I, et al. (2014) Assessment of chimpanzee adenovirus serotype 63 neutralizing antibodies prior to evaluation of a candidate malaria vaccine regimen based on viral vectors. Clin Vaccine Immunol 21: 901–903. https://doi.org/10.1128/CVI. 00723-13 PMID: 24739980
18. Sheehy SH, Duncan CJ, Elias SC, Collins KA, Ewer KJ, Spencer AJ, et al. (2011) Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors. Mol Ther 19: 2269–2276. https://doi.org/10.1038/mt.2011.176 PMID: 21862998
19. Bejon P, Mwacharo J, Kai OK, Todryk S, Keating S, Lang T, et al. (2006) Immunogenicity of the candidate malaria vaccines FP9 and modified vaccinia virus Ankara encoding the pre-erythrocytic antigen ME-TRAP in 1–6 year old children in a malaria endemic area. Vaccine 24: 4709–4715. https://doi.org/10.1016/j.vaccine.2006.03.029 PMID: 16621181
20. O’Hara GA, Duncan CJ, Ewer KJ, Collins KA, Elias SC, Halstead FD, et al. (2012) Clinical Assessment of a Recombinant Simian Adenovirus ChAd63: A Potent New Vaccine Vector. J Infect Dis 205: 772–781. https://doi.org/10.1093/infdis/jir850 PMID: 22275401
21. Sissoko MS, Healy SA, Katile A, Omaswa F, Zaidi I, Gabriel EE, et al. (2017) Safety and efficacy of PfSPZ Vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial. Lancet Infect Dis 17: 498–509. https:// doi.org/10.1016/S1473-3099(17)30104-4 PMID: 28216244
22. Hodgson SH, Ewer KJ, Bliss CM, Edwards NJ, Rampling T, Anagnostou NA, et al. (2015) Evaluation of the Efficacy of ChAd63-MVA Vectored Vaccines Expressing Circumsporozoite Protein and ME-TRAP Against Controlled Human Malaria Infection in Malaria-Naive Individuals. J Infect Dis 211: 1076–1086. https://doi.org/10.1093/infdis/jiu579 PMID: 25336730
23. Lyke KE, Fernandez-Vina MA, Cao K, Hollenbach J, Coulibaly D, Kone AK, et al. (2011) Association of HLA alleles with Plasmodium falciparum severity in Malian children. Tissue Antigens 77: 562–571. https://doi.org/10.1111/j.1399-0039.2011.01661.x PMID: 21447146
24. Hill AV, Allsopp CE, Kwiatkowski D, Anstey NM, Twumasi P, Rowe PA, et al. (1991) Common west African HLA antigens are associated with protection from severe malaria. Nature 352: 595–600. https://doi.org/10.1038/352595a0 PMID: 1865923
25. May J, Lell B, Luty AJ, Meyer CG, Kremsner PG (2001) HLA-DQB1*0501-restricted Th1 type immune responses to Plasmodium falciparum liver stage antigen 1 protect against malaria anemia and reinfections. J Infect Dis 183: 168–172. https://doi.org/10.1086/317642 PMID: 11076705
26. Gola A, Silman D, Walters AA, Sridhar S, Uderhardt S, Salman AM, et al. (2018) Prime and target immunization protects against liver-stage malaria in mice. Sci Transl Med 10.